Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03151161
Recruitment Status : Unknown
Verified June 2018 by Hao Long, Sun Yat-sen University.
Recruitment status was:  Not yet recruiting
First Posted : May 12, 2017
Last Update Posted : June 7, 2018
Sponsor:
Information provided by (Responsible Party):
Hao Long, Sun Yat-sen University

Brief Summary:

EGFR-tyrosine kinase inhibitor(TKI)- ie, erlotinib, gefitinib, icotinib,has been recommended as the first option for EGFR-mutated IIIb/IV NSCLC by serial trials as it prolonged patients' progression-free survival. The OPTIMAl trial indicated that those who received TKI and chemotherapy during the whole treatment window survived longest. Unfortunately, previous studies(INTACT, TRIBUTE et al) that concurrently combined TKI and cytotoxic regimens failed to improve survival in unselected patients. To avoid the potential synergistic antagonism, the FAST-ACT II trial committed a sequential strategy and find a superiority in the combination arm upon chemotherapy even in EGFR-mutated group. However, pharmaceutically, the continuous administration of an EGFR-TKI before subsequent chemotherapy in FAST-ACT II could obviate the effects of cytotoxic agents due to the erlotinib-induced G1 arrest.

On the basis of these and other studies, the investigators hypothesized that a better sequential combination strategy of EGFR-TKI and chemotherapy (adding a EGFR-TKI wash-out window before chemotherapy) would be more efficacious than chemotherapy alone. In this study, the investigators investigate the efficacy(PFS:progression free survival), safety, and adverse-event profile of chemotherapy plus intermittent and maintenance of icotinib compared with icotinib single drug, when these drugs were used as first-line treatment in who had non-squamous lung carcinoma with EGFR gene mutation in China.


Condition or disease Intervention/treatment Phase
Lung, Carcinoma Drug: Icotinib,Pemetrexed,Carboplatin Drug: Icotinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective,Multi-center, Open-labeled Phase 2 Randomized and Comparative Clinical Study of First Line Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in ⅢB/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Study Start Date : December 2015
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental Group
  1. Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;
  2. Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression.
Drug: Icotinib,Pemetrexed,Carboplatin
Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression

Active Comparator: Control Group
Single drug: Icotinib 125mg, three times a day, continous until disease progression
Drug: Icotinib
Single drug: Icotinib 125mg, three times a day, continuous until disease progression.




Primary Outcome Measures :
  1. Response Evaluation Criteria in Solid Tumors(RECIST) 1.1 [ Time Frame: eight weeks ]
    Patients were images with computed tomography (CT) scan



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Present with histologically proven diagnosis of non-Squamous NSCLC Stage IIIB or IV as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer, that is not amenable to curative therapy, such as surgery or radiotherapy and so on.
  • Confirmed activating mutation of EGFR-ie, an exon 19 deletion or an exon 21 L858R point mutation.
  • Measurable lesions according to RECIST 1.1 criteria.
  • Patients between 18 and 75 years of age.
  • Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1.
  • Estimated life expectancy of ≥12 weeks.
  • Haematological stable: ANC > 1.5; PLT > 100; HGB > 90 g/L.
  • Adequate liver function: total bilirubin < 1.5 x ULN; AST and ALT < 2.5 x ULN (without liver metastasis); or AST and ALT < 5 x ULN (with liver metastasis).
  • Adequate renal function: creatinine < 1.5 x ULN; CCR >= 50ml/min; and urine protein < 2+; for the patients with urine protein >= 2+, 24 hours total urine protein <= 1g.
  • INR <= 1.5; aPTT < 1.5 x ULN, within 7 days before treatment.
  • For female patients, pregnancy test (blood or urine) needs to be done within 7 days before treatment; if negative, patients need to be consented for proper contraception throughout the treatment and 8 weeks after the completion of treatment. For male patients, they also need to be consented for proper contraception throughout the treatment and 8 weeks after the completion of treatment.
  • Signed informed consent document on file.
  • Patient compliance and geographic proximity that allow adequate follow up.

Exclusion Criteria:

  • Histology is confirmed to be squamous cell carcinoma, mixed NSCLC and SCLC, or squamous cell carcinoma dominant adenosquamous carcinoma.
  • Patients previously had targeting HER therapy, including erlotinib, gefitinib, cetuximab,trastuzumab, etc.
  • Patients previously had systemic therapy for NSCLC before study, including cytotoxic medicine, target therapy, or other medicines in a clinical trial.
  • Physiological incompetence with upper gastrointestinal tract, or malabsorption syndrome, or intolerance of oral drugs, or active peptic ulceration.
  • Clinically moderate to severe COPD, active ILD or other pulmonary diseases defined by researchers.
  • Uncontrolled ocular inflammation or infection, or other conditions that could lead to ocular inflammation or infection.
  • Conditions or risk factors that contraindicate the research medicines.
  • Any unsteady systematic diseases, including active infection, uncontrolled high blood pressure, unstable angina, recent angina (within 3 months), congestive heart failure, ischemic heart diseases (within 6 months), severe arrhythmia, severe liver/renal/metabolic diseases.
  • Known HIV infection.
  • Unhealed wound, active peptic ulceration or fracture.
  • Pregnancy or lactation.
  • Female patients who refuse contraception throughout treatment and 6 months after the treatment; male patients who refuse contraception throughout treatment and 90 days after the treatment.
  • Known severe hypersensitivity to Icotinib, Pemetrexed or Carboplatin.
  • Patients with esophago-tracheal fistula.
  • Pleural effusion or pericardiac effusion that cannot be controlled by drainage or other procedures.
  • Inability to comply with protocol or study procedures.
  • A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
  • Patients had other malignancies apart from NSCLC, except cervical cancer in situ, skin basal cell carcinoma or squamous cell carcinoma, prostate cancer or breast ductal carcinoma in situ that have been adequately treated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03151161


Contacts
Layout table for location contacts
Contact: Hao Long, Prof +86 20 87343261 longhao@sysucc.org.cn
Contact: Ruping Xing +86 20 87343736 xingrp@sysucc.org.cn

Locations
Layout table for location information
China, Guangdong
Guanzhou, Guangdong, China, 510000
Contact: Long Hao, Prof    +86 2087343261    longhao@sysucc.org.cn   
Contact: Ruping Xing    +86 2087343736    xingrp@sysucc.org.cn   
Sponsors and Collaborators
Sun Yat-sen University
Layout table for additonal information
Responsible Party: Hao Long, Sun Yat-sen University Cancer Center, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03151161    
Other Study ID Numbers: 201512001
First Posted: May 12, 2017    Key Record Dates
Last Update Posted: June 7, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Hao Long, Sun Yat-sen University:
chemotherapy
maintenance therapy
icotinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carboplatin
Pemetrexed
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors